The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Women's health is in fact a direct reflection of the nation's overall health
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Subscribe To Our Newsletter & Stay Updated
